GlassScriptPhysician profile
Philip E Sekunda
NPI 1548594864
$1,579.44
in general payments reported to CMS, 2019-2025
13 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $310 · 2022: $383 · 2023: $230 · 2024: $198 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $885.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $426.21 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $248.63 | 2021-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $242.83 | 2023-2025 | Tezspire, Fasenra |
| Grifols USA, LLC | $239.36 | 2022-2025 | Prolastin-C Liquid |
| Pfizer INC. | $120.71 | 2021-2024 | |
| Boston Scientific Corporation | $82.03 | 2021-2025 | Watchman Access System |
| Abiomed | $77.75 | 2025 | |
| Abbvie INC. | $34.69 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $32.14 | 2022 | |
| Ucb, INC. | $30.78 | 2024 | Briviact |
| E.R. Squibb & Sons, L.L.C. | $17.00 | 2024 | Eliquis |
| Merck Sharp & Dohme LLC | $13.81 | 2023 | Dificid, Zerbaxa, Recarbrio |
| Ferring Pharmaceuticals INC. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Sekunda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.